ArticleClinical rheumatology2026
Initial assessment of blood-brain barrier permeability alterations and associated clinical characteristics in patients with primary Sjögren's syndrome: Insights from DCE-MRI.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo quantitatively evaluate blood-brain barrier (BBB) permeability alterations in primary Sjögren's syndrome (pSS) using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and their associations with clinical immune-inflammatory indicators.
methodsIn this retrospective study, 19 pSS patients and 23 controls underwent 3.0 T DCE-MRI. BBB permeability was quantified using voxel-wise K
resultsVoxel-wise analysis using TFCE correction (P_TFCE < 0.05) identified significantly elevated K
conclusionThis study provides the first in vivo DCE-MRI evidence of focal BBB permeability alterations in pSS, potentially associated with immune activation and systemic inflammation. These preliminary findings suggest that DCE-MRI may enable early detection of subclinical central nervous system involvement in pSS and provide insights into its underlying neuroimmunological mechanisms. Key Points • First in vivo DCE-MRI evidence of focal BBB permeability alterations in pSS. • Elevated Ktrans values, especially in the right cerebellum, were correlated with serum globulin and ESR levels, suggesting that BBB alterations may be associated with immune activation and systemic inflammation. • DCE-MRI may serve as a sensitive, noninvasive tool for detecting subclinical CNS involvement in pSS.
Indexed as
Identifiers
41239077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.